Faeth Therapeutics, Inc. Common Stock (FTH) Stock Price
FTHStock
$34.52+166.08%52W
Market Cap$892.01M
P/E—
PEG Ratio—
Div yield—
Beta2.10
FTH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)143.00%
Price vs S&P 500 (4W)16.10%
VGM Score65.39
FTH Earnings Surprise History
Q2 25-3.91est. -5.00
Q3 25-3.62est. -4.11
Q4 25-3.74est. -4.81
Q1 26-131.45est. -0.62
Q2 26-2.84est. -4.76
FTH Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.13
4.30
4.36
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FTHFaeth Therapeutics, Inc. Common Stock | — | — | B | $34.52 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Faeth Therapeutics, Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.